Heart failure hope for Novartis first-in-class neprilysin inhibitor
This article was originally published in Scrip
Executive Summary
Novartis may be able to plug the gap in treatments for heart failure with preserved ejection fraction with its novel product LCZ696, based on positive effects on a surrogate marker in a Phase II trial presented this weekend at the European Society of Cardiology meeting in Munich.